Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Protara Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
TARA
Nasdaq
2834
www.protaratx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Protara Therapeutics, Inc.
Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
- Feb 5th, 2025 1:00 pm
Protara Highlights Recent Updates and Anticipated 2025 Milestones
- Jan 13th, 2025 1:00 pm
Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Jan 8th, 2025 1:00 pm
Protara Announces Closing of $100 Million Public Offering
- Dec 11th, 2024 9:05 pm
Protara Announces Pricing of $100 Million Public Offering
- Dec 10th, 2024 4:35 am
Protara Announces Proposed Public Offering
- Dec 9th, 2024 9:01 pm
Institutions profited after Protara Therapeutics, Inc.'s (NASDAQ:TARA) market cap rose US$60m last week but individual investors profited the most
- Dec 7th, 2024 1:37 pm
Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
- Dec 5th, 2024 12:00 pm
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024
- Dec 3rd, 2024 1:00 pm
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
- Nov 15th, 2024 10:52 pm
Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
- Nov 12th, 2024 1:00 pm
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
- Nov 6th, 2024 1:00 pm
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support
- Oct 21st, 2024 12:00 pm
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
- Sep 9th, 2024 12:05 pm
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
- Sep 9th, 2024 12:00 pm
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Sep 3rd, 2024 12:00 pm
Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?
- Aug 8th, 2024 10:47 am
Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
- Aug 6th, 2024 12:00 pm
Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Jun 24th, 2024 9:06 pm
Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
- May 21st, 2024 12:00 pm
Scroll